欧美精品在线第一页,久久av影院,午夜视频在线播放一三,久久91精品久久久久久秒播,成人一区三区,久久综合狠狠综合久久狠狠色综合,成人av一区二区亚洲精,欧美a级在线观看

Higher doses of radiation don't improve survival in prostate cancer: study

Source: Xinhua| 2018-03-16 06:07:14|Editor: yan
Video PlayerClose

CHICAGO, March 15 (Xinhua) -- Compared with standard radiation treatment, higher doses of radiation do not improve survival for many patients with prostate cancer, a study led by researchers at Washington University School of Medicine in St. Louis shows.

The study included about 1,500 patients with intermediate-risk prostate cancer that most patients fall into. To be classified in this risk category, patients generally have PSA scores of 10-20 ng/ml and a Gleason score of seven.

Both treatment groups received external beam radiation. The standard group received a radiation dose of 70.2 gray delivered over 39 treatment visits. The investigational group received increasing doses up to 79.2 gray delivered over 44 visits. A gray is the standard measure of radiation a material has absorbed.

Of the 748 men receiving standard treatment, 75 percent were still alive after eight years of follow-up. Of the 751 men receiving the dose-escalation treatment, 76 percent were alive at the eight-year mark, a difference that is not statistically significant.

Over the course of the study, 51 patients died of prostate cancer, which is 3.4 percent of all patients enrolled. At the eight-year mark, the death rate due to prostate cancer for patients receiving standard treatment was four percent compared with two percent for patients receiving the escalating dose. These rates also were not statistically different.

While there was no difference in overall survival numbers, Jeff M. Michalski, first author and professor of radiation oncology of Washington University, pointed out some differences in side effects and in whether further treatment was needed later.

Patients in the standard dose group were more likely to undergo further therapies to control tumors that had grown larger or that had spread to another site in the body. While patients in the escalating dose group experienced more side effects, such as urinary irritation or rectal bleeding, sometimes years after treatment.

During the 10 years it took to enroll enough patients in the trial, at least six new therapies were approved for recurrent or metastatic prostate cancer, and these therapies have been shown to improve survival.

"If there is a difference between standard and escalating doses, it's hard to show it when the patients who later develop recurrent cancer can have their lives extended through the use of additional therapies," said Michalski.

The study, the first that is large enough to examine whether these improved measurements translate into longer survival for patients, is published Thursday in JAMA Oncology.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011105521370422301
主站蜘蛛池模板: 久久国产精品视频一区| 99国产精品| 欧美日韩国产一区在线| 午夜三级电影院| 欧美一区二区三区国产精品| 日韩欧美一区二区久久婷婷| 久久99国产综合精品| 亚洲国产精品美女| 久久福利免费视频| 亚洲国产99| 日韩av中文字幕在线免费观看| 国产白丝一区二区三区| 日韩精品中文字幕久久臀| 日韩精品中文字幕久久臀| 91久久精品国产亚洲a∨麻豆| 国产精品一区二区毛茸茸| 中文字幕一区二区三区又粗| 狠狠色噜狠狠狠狠| 国产精品v亚洲精品v日韩精品| 99久久免费毛片基地| 国产精品色在线网站| 91精品久久久久久综合五月天 | 欧美日韩国产精品一区二区| 在线电影一区二区| 国产乱子伦农村xxxx| 中文天堂在线一区| 日韩av在线网| 麻豆9在线观看免费高清1| 午夜黄色一级电影| 色综合欧美亚洲国产| 久久人人97超碰婷婷开心情五月| 国产精品久久久久久久久久久杏吧 | 欧美久久久一区二区三区| 国语对白一区二区三区| 国产老妇av| 91精品夜夜| 国产原创一区二区 | 中文字幕+乱码+中文字幕一区| 国产精品国精产品一二三区| 国产欧美日韩精品一区二区三区| 亚洲国产一二区| 国产电影精品一区二区三区| 中文字幕日韩一区二区| 狠狠色丁香久久婷婷综| 久久精品国产一区二区三区不卡| 91人人爽人人爽人人精88v| 狠狠躁夜夜躁xxxxaaaa| 综合久久激情| 亚洲精品一区二区三区香蕉| 欧洲激情一区二区| 91久久精品在线| 欧美乱妇在线视频播放| 亚洲欧美一区二区精品久久久| 欧美一区亚洲一区| 丝袜脚交一区二区| 欧美亚洲另类小说| 国产91精品高清一区二区三区| 亚洲精品乱码久久久久久按摩| 国产日韩欧美一区二区在线观看| 日本看片一区二区三区高清| 欧美日韩中文不卡| 国产黄一区二区毛片免下载| 午夜毛片影院| 欧美日韩一区二区三区免费| 亚洲s码欧洲m码在线观看| 国产69精品福利视频| 免费午夜在线视频| 少妇性色午夜淫片aaa播放5| 欧美二区在线视频| 欧美一区二区三区艳史| 日韩精品久久一区二区| 午夜看片在线| 狠狠色噜噜狠狠狠狠2021免费| 456亚洲精品| 99精品免费在线视频| 91久久免费| 国产精品亚洲二区| 97国产精品久久| 蜜臀久久99精品久久一区二区| 午夜影院试看五分钟| 欧美一区二区三区四区夜夜大片| 999久久久国产|